The Pharmacy Times® Gastrointestinal resource center provides news and articles centered around the FDA approved drugs in gastroenterology, as well as links to condition-specific resources, and videos and other content.
What can we help you find?
Shared insight on the open dialogues that should take place between patients with opioid-induced constipation and care providers.
Key opinion leaders provide their perspectives on the goals of therapy and prophylactic management of opioid-induced constipation.
A comprehensive review of opioid-induced constipation diagnosis strategies and foundational treatment guidelines.
A panel of experts considers the disease pathology of opioid-induced constipation and the burden it has on patients.
After some lots of ranitidine were found to contain small amounts of N-nitrosodimethylamine (NDMA), Novartis's Sandoz unit has announced that they are halting distribution of ranitidine (Zantac) products until the contamination concerns are resolved.
Officials from the FDA have announced an approved package size and package type limit for over-the-counter (OTC) brand-name tablet and capsule forms of loperamide.
An over-the-counter and prescription drug, ranitidine is an H2 (histamine-2) blocker that decreases the amount of acid created by the stomach.
A major reason patients visit their primary care providers is constipation. Often, the constipation is acute and prescribers can identify an underlying cause and correct it. Even more often, there is no underlying cause and the patient is diagnosed with chronic idiopathic constipation (CIC).
Health care professionals can play an important role in managing patients with diarrhea by recommending OTC products for initial treatment.
Pharmacists are instrumental in guiding patients on the appropriate and safe use of products for gastrointestinal discomfort.
Just 22% of those who suffer seek help from a health care provider, newer agents show promise.
Diet and lifestyle changes are key components of treating gastroesophageal reflux disease.